Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 87

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 3
Chunk 87
---
— — — 974 Change in noncontrolling interest— — — — — — 4 4 Balance at December 31, 20231,766 18 (6,533)20,180 (1,000)(2,305)37 10,397 Net earnings attributable to AbbVie Inc.— — — — 4,278 — — 4,278 Other comprehensive income, net of tax— — — — — 380 — 380 Dividends declared— — — — (11,178)— — (11,178)Purchases of treasury stock(9)— (1,703)— — — — (1,703)Stock-based compensation plans and other8 — 35 1,153 — — — 1,188 Change in noncontrolling interest— — — — — — 2 2 Balance at December 31, 20241,765 $18 $(8,201)$21,333 $(7,900)$(1,925)$39 $3,364 

The accompanying notes are an integral part of these consolidated financial statements.

2024 Form 10-K   |  54

AbbVie Inc. and Subsidiaries

Consolidated Statements of Cash Flows years ended December 31 (in millions) (brackets denote cash outflows)202420232022Cash flows from operating activitiesNet earnings$4,286 $4,873 $11,845 Adjustments to reconcile net earnings to net cash from operating activities:Depreciation764 752 778 Amortization of intangible assets7,622 7,946 7,689 Deferred income taxes(1,449)(2,889)(1,931)Change in fair value of contingent consideration liabilities3,771 5,128 2,761 Payments of contingent consideration liabilities(1,995)(870)(164)Stock-based compensation911 747 671 Acquired IPR&D and milestones2,757 778 697 Gain on divestitures— — (172)Non-cash litigation reserve adjustments, net of cash payments508 (443)2,243 Impairment of intangible assets4,476 4,229 770